NIAMS P30 Centers Program (P30 - Clinical Trial Not Allowed)
National Institutes of Health
Classification and identifiers
- Solicitation number
- RFA-AR-27-001
- Assistance listing (CFDA)
- 93.313
Amount
Amount not published by the funder
Who can apply
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
About this opportunity
The overall goal of this program is to accelerate scientific discovery, improve research efficiency, and enhance the translation of research findings into improved health outcomes. Centers funded under this program will also foster multidisciplinary collaboration, support workforce development across career stages, and promote training in emerging areas such as data science, artificial intelligence, and implementation research. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) requests applications for the NIAMS P30 Centers Program to support integrated research Centers within its mission areas of skin biology and diseases; bone, muscle, and orthopaedic research; and rheumatic diseases. The NIAMS P30 Centers Program supports Centers that provide coordinated ...
Related opportunities
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)National Institutes of HealthCloses Apr 2027
- NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)National Institutes of Health
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)National Institutes of HealthCloses Nov 2026Up to $150K
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)National Institutes of HealthCloses Nov 2026Up to $300K
- NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)National Institutes of HealthCloses Apr 2029
- National Biomedical Research Centers (P50 Clinical Trial Optional)National Institutes of HealthUp to $11.4M